logo
Is There a Medicare Drug Price List?

Is There a Medicare Drug Price List?

Health Line16-07-2025
Currently, there's no universal Medicare drug price list available, as drug costs and availability vary according to the private insurer administering the Part D prescription drug plan.
Contact Part D prescription drug plan providers to view a Medicare drug price list to discuss their coverage options.
They can advise on the drugs they offer and the associated costs.
Drug prices in Medicare Part D plans
Part D drug plans may include various out-of-pocket costs, including premiums, deductibles, coinsurances, and copayments. However, in 2025, no plan may have a deductible above $590.
There are three stages to Part D plans:
The deductible stage: Not all Part D plans have a deductible, but if your plan does, you must begin at this stage.
The initial coverage stage: Once you pay your deductible in full, you must pay a 25% coinsurance toward the cost of your medications. Some plans may have different coinsurance amounts.
The catastrophic coverage stage: Once you pay $2,000 in out-of-pocket expenses, you enter the catastrophic coverage stage and pay no more toward your medications for the remaining calendar year. In 2026, the out-of-pocket total may increase to $2,100.
How Part D drug plans list their prices
If you have a Medicare Part D prescription drug plan, a private insurer can administer it on Medicare's behalf. The company must follow specific Medicare rules and processes, but it can set costs and decide which drugs to offer.
Each plan has a drug list, known as a formulary, that details the drugs it covers. Formularies typically operate on a tier system, with more expensive medications in higher tiers.
While plan providers can decide which drugs to include in their formularies, per Medicare rules, they must offer some medications, including at least two drugs in the most commonly prescribed categories and classes. Additionally, all plans must offer most of the drugs in specific protected classes. Protected classes include:
antidepressants
anticonvulsants
antipsychotics
cancer medications
HIV medications
immunosuppressants for organ transplants
Before enrolling in a Part D plan, it's important to review the formularies from different companies to ensure that they include your prescription medications. If they're unavailable, you may need to pay out of pocket.
Part D plan formularies explained
Medicare formularies categorize drugs into different tiers. Tiers may include:
generic medications
preferred brand-name medications
nonpreferred brand-name medications
specialty medications
Each drug tier may usually have different out-of-pocket costs, with lower tier drugs often having lower copayments or coinsurances.
What to ask Part D plan providers
Here are some questions to keep in mind when researching different Medicare Part D plan options.
What to ask potential Part D plan providers
Are my prescription medications in the formulary?
What tier are my medications?
What are my cost-sharing responsibilities?
Are there any restrictions applicable to my medications?
How much is the monthly premium?
Frequently asked questions
Here are some common questions and answers about Medicare drug price lists.
Takeaway
There's no specific Medicare drug price list, but drug lists are available from Medicare Part D prescription drug plan providers.
By exploring all available options for Part D drug plans, including the medications listed in plan formularies, you can make informed decisions about your drug coverage and choose a plan that meets your medication and budget needs.
The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Yahoo

time21 minutes ago

  • Yahoo

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio

Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

Yahoo

time21 minutes ago

  • Yahoo

Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 app where AI will automatically identify the ingredients and populate the meal description SAN DIEGO, July 28, 2025--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now simply take a photo of their food in the app where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the only prescription continuous glucose monitor in the U.S. to support photo logging2,3. "Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals," said Jake Leach, president and chief operating officer at Dexcom. "Smart Food Logging has long been a highly requested feature from users across our product portfolio, so we're excited to bring it to market and hope this enhanced tracking feature makes managing glucose levels even simpler." The addition of Smart Food Logging is yet another demonstration of Dexcom's commitment to continued innovation and AI. This new feature joins other recently announced enhancements across Dexcom's glucose biosensing portfolio, including: Weekly Insights in Stelo: The first GenAI feature in Stelo, which offers users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app. Stelo integration with Oura: The first-ever integration of glucose biosensing data in the Oura app. When Stelo is synced with Oura, users have a holistic view of their body's biometrics, now including glucose. This integration empowers users to understand the impact of different health behaviors and work towards optimal metabolic health. Customizable target range in Dexcom G7: A new feature that enables users to adjust their glucose target ranges in Clarity Card within the Dexcom G7 app, beyond default settings – allowing for greater personalization across user groups. Glucose Impact in Dexcom G7 and Stelo: Glucose Impact offers a new focused view for logged events to see a clearer picture and gain a deeper understanding of how meals, activities, and sleep patterns affect your glucose levels. Stelo and Dexcom G7 users can now access the Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR 1 Dexcom, Stelo User Guide, 2024. 2 Based on Freestyle Libre User Guides. 3 Based on Medtronic User Guides. View source version on Contacts Media Relations Contact Nadia Conardmediarelations@ Investor Relations Contact Sean Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Adia Nutrition Inc. Celebrates Approval as Aetna Health Insurance Provider and Anticipates United Healthcare Approval for Adia Med Subsidiary
Adia Nutrition Inc. Celebrates Approval as Aetna Health Insurance Provider and Anticipates United Healthcare Approval for Adia Med Subsidiary

Yahoo

time21 minutes ago

  • Yahoo

Adia Nutrition Inc. Celebrates Approval as Aetna Health Insurance Provider and Anticipates United Healthcare Approval for Adia Med Subsidiary

Winter Park, Florida--(Newsfile Corp. - July 28, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has been approved as an in-network provider for Aetna health insurance, effective Friday, July 25, 2025. Additionally, Adia Med remains on track for approval as a provider with United Healthcare by this Friday, August 1, 2025, marking significant milestones in expanding access to its cutting-edge regenerative therapies and nutritional services. Aetna HealthTo view an enhanced version of this graphic, please visit: This approval with Aetna allows Adia Med to serve approximately 39 million members across the United States, tapping into Aetna's extensive network of 1.8 million health professionals, including 828,000 primary care providers and specialists, and over 6,200 hospitals. Aetna's health plans, with Affordable Care Act (ACA) marketplace plans averaging $647 monthly, provide robust coverage for services like Medical Nutrition Therapy (MNT) and regenerative treatments, aligning with Adia Med's offerings in chronic disease management and advanced therapies such as Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Therapeutic Plasma Exchange (TPE). Adia Med is also in the final stages of approval with United Healthcare, the nation's largest health insurer with a 15% market share, serving millions of members. This anticipated approval by August 1, 2025, will further broaden access to Adia Med's innovative treatments, including stem cell therapies and nutritional counseling, for a vast patient population. The company has already begun submitting its first patient insurance claims through United Healthcare, signaling imminent integration into their network. Financial Impact of Insurance Partnerships Aetna processes claims for its 39 million members, with annual medical expenditures estimated in the tens of billions of dollars, covering hospitalization, surgical, medical, vision, and prescription drug expenses. United Healthcare similarly manages billions in annual medical payouts, supporting a wide range of services from primary care to specialized treatments. These partnerships position Adia Nutrition and its Adia Med subsidiary to access significant reimbursement pathways, enhancing affordability and reach for its regenerative medicine and nutritional services. "We are overjoyed to join Aetna's provider network and are eagerly awaiting our approval with United Healthcare," said Larry Powalisz, CEO of Adia Nutrition Inc. "These partnerships validate the clinical excellence of Adia Med's regenerative therapies and nutritional programs, enabling us to deliver transformative care to millions while driving scalable growth in the $15.1 billion global stem cell market." For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical (X): @ADIA_NutritionSafe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store